Prospects for a vaccine in allergic diseases and asthma

BioDrugs

Volumn 13, Issue 1, 2000, Pages 61-75

  Bousquet, Jean ^a   Yssel, Hans ^a   Demoly, Pascal ^a  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTISENSE OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 4; INTERLEUKIN 5;

ALLERGY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PURIFICATION; ASTHMA; CELL INTERACTION; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0033977210     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200013010-00006     Document Type: Review

References (137)

1. 1. Bousquet J, Lockey R, Malling H. Allergen immunotherapy: therapeutic vaccines for allergic diseases. WHO Position Paper. J Allergy Clin Immunol 1998; 102: 558-62
2. 2. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases [see comments]. Immunol Today 1995; 16: 34-8
3. 3. Rapoport MJ, Jaramillo A, Zipris D, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993; 178: 87-99
4. 4. O'Garra A, Steinman L, Gijbels K. CD4+ T-cell subsets in autoimmunity. Curr Opin Immunol 1997; 9: 872-83
5. 5. Scheiner O, Kraft D. Basic and practical aspects of recombinant allergens. Allergy 1995; 50: 384-92
6. 6. Valenta R, Kraft D. Recombinant allergens for diagnosis and therapy of allergic diseases. Curr Opin Immunol 1995; 7: 751-6
7. 7. van Ree R. Analytic aspects of the standardization of allergenic extracts. Allergy 1997; 52: 795-805
8. 8. Valenta R, Almo S, Ball T, et al. The immunoglobulin E-allergen interaction: a target for therapy of type I allergic diseases, Int Arch Allergy Immunol 1998; 116: 167-76
9. 9. Smith A, Chapman M. Allergen specific immunotherapy: new strategies using recombinant allergens. In: Yssel JBAH, editor. Immunotherapy in asthma. New York: Marcel Dekker, 1998: in press
10. 10. de-Vries JE, Gauchat J-F, Aversa G, et al. Regulation of IgE synthesis by cytokines. Curr Opin Immunol 1992; 3: 851-8
11. 11. Pene J, Rousset F, Briere F, et al. IgE production by normal human B cells induced by alloreactive T cell clones is mediated by IL-4 and suppressed by IFN-gamma. J Immunol 1988; 141: 1218-24
12. 12. Del-Prete G, Maggi E, Parronchi P, et al. IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants. J Immunol 1988; 140: 4193-8
13. 13. Vercelli D, Jabara HH, Arai K-I, et al. Endogenous interleukin 6 plays an obligatory role in interleukin 4-dependent human IgE synthesis. Eur J Immunol 1989; 19: 1419
14. 14. Gascan H. Gauchat JF, de Waal-Malefyt R, et al. Regulation of human IgE synthesis. Clin Exp Allergy 1991; 1: 162-6
15. 15. Punnonen J, Aversa G, Cocks BG, et al. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 1993; 90: 3730-4
16. 16. de Waal-Malefyt R, Abrams JS, Zurawski SM, et al. Differential regulation of TL-13 and IL-4 production by human CD8+ and CD4+ Th0, Th1 and Th2 T cell clones and EBV-transformed B cells. Int Immunol 1995; 7: 1405-16
17. 17. Punnonen J, Yssel H, de Vries J. The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4+ and CD8+ T cells. J Allergy Clin Immunol 1997; 100: 792-801
18. 18. Zurawski SM, Vega Jr F, Huyghe B, et al. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J 1993; 12: 3899-905
19. 19. Ma X, Aste-Amezaga M, Gri G, et al. Immunomodulatory functions and molecular regulation of IL-12. Chem Immunol 1997: 68: 1-22
20. 20. Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol Today 1991; 12: 256-7
21. 21. Punnonen J, Aversa G, Vanderkerckhove B, et al. Induction of isotype switching and Ig production by CD5+ and CD10+ human fetal B cells. J Immunol 1992; 148: 3398-404
22. 22. MacGlashan Jr D, White JM, Huang SK, et al. Secretion of IL-4 from human basophils. The relationship between IL-4 mRNA and protein in resting and stimulated basophils. J Immunol 1994; 152: 3006-16
23. 23. Kasaian MT, Clay MJ, Happ MP, et al. IL-4 production by allergen-stimulated primary cultures: identification of basophils as the major IL-4-producing cell type. Int Immunol 1996; 8: 1287-97
24. 24. Gauchat J-F, Aubry JP, Mazzeci G. Human CD40-ligand: molecular cloning, cellular distribution and regulation of expression by factor controlling IgE production. FEBS Lett 1993; 315: 259-66
25. 25. Yssel H, Abbal C, Pène J, et al. The role of IgE in asthma. Clin Exp Allergy 1998; 28 Suppl. 5: 104-9
26. 26. Platts-Mills TA, Vervloet D, Thomas WR, et al. Indoor allergens and asthma: report of the Third International Workshop. J Allergy Clin Immunol 1997; 100: S2-24
27. 27. Anto JM, Sunyer J. Thunderstorms: a risk factor for asthma attacks [editorial; comraent]. Thorax 1997; 52: 669-70
28. 28. Burrows B, Martinez FD, Halonen M, et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N EngI J Med 1989; 320: 271-7
29. 29. Bousquet J, Yssel H, Vignola AM, et al. New developments in the immunology of asthma, with a focus on mechanisms and treatment. Curr Opin Pulmon Med 1997; 3: 42-50
30. 30. Norman PS, Lichtenstein LM. The clinical and immunologic specificity of immunotherapy. J Allergy Clin Immunol 1978; 61: 370-7
31. 31. Golden DB, Meyers DA, Kagey-Sobotka A, et al. Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy. J Allergy Clin Immunol 1982; 69: 489-93
32. 32. Van der Zee JS, Aalberse RC. The role of IgG in immediate-type hypersensitivity. Eur Respir J Suppl 1991; 13: 91s-96s
33. 33. Secrist H, Chelen CJ, Wen Y, et al. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993; 178: 2123-30
34. 34. Akdis C, Akdis M, Blesken T, et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996; 98: 1676-83
35. 35. Varney VA, Hamid QA. Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92: 644-51
36. 36. McHugh SM, Deighton J, Stewart AG, et al. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995; 25: 828-38
37. 37. Jutel M, Pichler WJ, Skrbic D, et al. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995; 154: 4187-94
38. 38. Hedlin G, Silber G, Naclerio R, et al. Comparison of the in-vivo and in-vitro response to ragweed immunotherapy in children and adults with ragweed-induced rhinitis. Clin Exp Allergy 1990; 20: 491-500
39. 39. Bousquet J, Becker WM, Hejjaoui A, et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. J Allergy Clin Immunol 1991; 88: 43-53
40. 40. Malling H. Local immunotherapy. EAACI-ESPACI Position Paper. Allergy 1998; 53: 933-44
41. 41. Van Wilsem EJ, Van Hoogstraten IM, Breve J, et al. Dendritic cells of the oral mucosa and the induction of oral tolerance. A local affair. Immunology 1994; 83: 128-32
42. 42. Hasseus B, Dahlgren U, Bergenholtz G, et al. Antigen presenting capacity of Langerhans cells from rat oral epithelium. J Oral Pathol Med 1995; 24: 56-60
43. 43. van Halteren AG, van der Cammen MJ, Cooper D, et al. Regulation of antigen-specific IgE, IgG1, and mast cell responses to ingested allergen by mucosal tolerance induction. J Immunol 1997; 159: 3009-15
44. 44. Bieber T. Fc epsilon RI on human epidermal Langerhans cells: an old receptor with new structure and functions. Int Arch Allergy Immunol 1997; 113: 30-4
45. 45. Stingl G, Maurer D. IgE-mediated allergen presentation via Fc epsilon R1 on antigen-presenting cells. Int Arch Allergy Immunol 1997; 113: 24-9
46. 46. Macatonia SE, Hosken NA, Litton M, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ Tcells. J Immunol 1995; 154: 5071-9
47. 47. van Wilsem E, van Hoogstraten I, Breve J, et al. In vivo antigen presentation capacity of dendritic ceils from oral mucosa and skin draining lymph nodes. Adv Exp Med Biol 1994; 355: 63-7
48. 48. Vogel FR. Adjuvants in perspective. Dev Biol Stand 1998; 92: 241-8
49. 49. Jahn-Schmid B, Graninger M, Glozik M, et al. Immunoreactivity of allergen (Bet v 1) conjugated to crystalline bacterial cell surface layers (S-layers). Immunotechnology 1996; 2: 103-13
50. 50. Agren LC, Ekman L, Lowenadler B, et al. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J Immunol 1997, 158: 3936-46
51. 51. Anderson PM. Delivery systems for immunomodulatory proteins and peptides. BioDrugs 1997; 7 (1): 51-65
52. 52. Uchida T, Naito S, Horino A, et al. Ovalbumin coupled either with murine red blood cells or liposome induces IgG but not IgE antibody production. Dev Biol Stand 1998; 92: 353-63
53. 53. Walls AF. Liposomes for allergy immunotherapy? [editorial]. Clin Exp Allergy 1992; 22: 1-2
54. 54. McWilliam AS, Stewart GA. Production of multilamellar, small unilamellar and reverse-phase liposomes containing house dust mite allergens. Potential adjuvants in the immunotherapy of allergic disease. J Immunol Methods 1989; 121: 53-60
55. 55. Genin I, Barratt G, Tran XT, et al. Optimization and characterization of freeze-dried multilamellar liposomes incorporating different standardized allergen extracts. Allergy 1994; 49: 645-52
56. 56. Marsh DG, Norman PS, Roebber M, et al. Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps. J Allergy Clin Immunol 1981; 68: 449-59
57. 57. Patterson R, Suszko IM, Bacal E, et al. Reduced allergenicity of high molecular weight ragweed polymers. J Allergy Clin Immunol 1979; 63: 47-50
58. 58. Bousquet J, Maasch HJ, Hejjaoui A, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma. J Allergy Clin Immunol 1989; 84: 546-56
59. 59. Grammer LC, Shaughnessy MA, Shaughnessy JJ, et al. Allergenicity, immunogenicity, and safety of immunotherapy with various molecular weight ranges of polymerized ragweed. J Allergy Clin Immunol 1985; 76: 195-200
60. 60. Swoboda I, Jilek A, Ferreira F, et al. Isoforms of Bet v 1, the major birch pollen allergen, analyzed by liquid chromatography, mass spectrometry, and cDNA cloning. J Biol Chem 1995; 270; 2607-13
61. 61. Lowenstein H, Sparholt SH, Klysner SS, et al. The significance of isoallergenic variations in present and future specific immunotherapy. Int Arch Allergy Immunol 1995; 107: 285-9
62. 62. Schenk S, Hoffmann-Sommergruber K, Breiteneder H, et al. Four recombinant isoforms of Cor a i, the major allergen of hazel pollen, show different reactivities with allergen-specific T-lymphocyte clones. Eur J Biochem 1994; 224: 717-22
63. 63. Ferreira F, Ebner C. Isoforms of atopic allergens with reduced allergenicity but conserved T cell antigenicity: possible use for specific immunotherapy. Int Arch Allergy Immunol 1997; 113: 125-7
64. 64. Ferreira F, Hirtenlehner K, Jilek A, et al. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 2: potential use of hypoallergenic isoforms for immunotherapy. J Exp Med 1996; 183: 599-609
65. 65. Smith AM, Chapman MD. Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. Mol Immunol 1996; 33: 399-405
66. 66. Noguchi E, Shibasaki M, Nishiyama C, et al. Igh responsiveness to Dermatophagoides farinae in young asthmatic children: IgE binding study using recombinant allergens of Der f1, Der f2 and mutant proteins of Der f2. Int Arch Allergy Immunol 1996; 110: 380-7
67. 67. Ferreira F, Ebner C, Kramer B, et al. Modulation of IgE reactivity of allergens hy site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. Faseb J 1998; 12: 231-42
68. 68. Hakkaart GA, Aalberse RC, van Ree R. Epitope mapping of the house-dust-mite allergen Der p 2 by means of site-directed mutagenesis. Allergy 1998; 53: 165-72
69. 69. Smith AM, Chapman MD. Localization of antigenic sites on Der p 2 using oligonucleotide-directed mutagenesis targeted to predicted surface residues. Clin Exp Allergy 1997; 27: 593-9
70. 70. Gajhede M, Osmark P, Poulsen F, et al. X-ray and NMR structure of Bet v 1, the origin of birch pollen allergy. Nature Struct Biol 1996; 3: 1040-4
71. 71. Fedorov A, Ball T, Mahoney N, et al. Crystal structure and IgE-epitope mapping of birch pollen profilin: molecular basis for allergen cross-reactivity. Structure 1997; 15: 33-45
72. 72. Vrtala S, Hirtenlehwer K, Vangelista L, et al. Conversion of the major birch pollen allergen, Bet v 1, into two non-anaphylactic T cell epitope-containing fragments; candidates for a novel form of immunotherapy. J Clin Invest 1997; 99: 1673-81
73. 73. Yssel H, Johnson KE, Schneider PV, et al. T cell activation-inducing epitopes of the house dust mite allergen Der p I. Proliferation and lymphokine production patterns by Der p 1-specific CD4+ T cell clones. J Immunol 1992; 148: 738-45
74. 74. Yssel H, Fasler S, Lamb J, et al. Induction of non-responsiveness in human allergen-specific type 2 T helper cells. Curr Opin Immunol 1994; 6: 847-52
75. 75. Fasler S, Aversa G, de Vries JE, et al. Antagonistic peptides specifically inhibit proliferation, cytokine production, CD40L expression, and help for IgE synthesis by Der p 1-specific human T-cell clones. J Allergy Clin Immunol 1998; 101: 521-30
76. 76. Briner TJ, Kuo MC, Keating KM, et al. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci USA 1993; 90: 7608-12
77. 77. Hoyne GF, Callow MG, Kuo MC, et al. Characterization of T-cell responses to the house dust mite allergen Der p II in mice. Evidence for major and cryptic epitopes. Immunology 1993; 78: 65-73
78. 78. Schou C. T-cell epitopes of allergen molecules. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1994; 87: 247-9
79. 79. Valenta R, Vrtala S, Laffer S, et al. B-cell epitopes of allergens determined by recombinant techniques; use for diagnosis and therapy of type I allergy. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1994; 87: 235-46
80. 80. Hetzel C, Janssen R, Ely S, et al. Use of peptides to selectively modulate CD4+ T-cell responses. Biochem Soc Trans 1997; 25: 398-403
81. 81. O'Hehir RE, Hoyne GF, Thomas WR, et al. House dust mite allergy: from T-cell epitopes to immunotherapy. Eur J Clin Invest 1993; 23: 763-72
82. 82. Schad VC, Carman RD, Greenstein JL. The potential use of T cell epitopes to alter the immune response. Semin Immunol 1991; 3: 217-24
83. 83. van't Hof W, Driedijk PC, van den Berg M, et al. Epitope mapping of the Dermatophagoides pteronyssinus house dust mite major allergen Der p II using overlapping synthetic peptides. Mol Immunol 1991; 38: 1225-32
84. 84. Jeannin P, Didierlaurent A, Gras-Masse H, et al. Specific histamine release capacity of peptides selected from the modelized Der p I protein, a major allergen of Dermatophagoides pteronyssinus. Mol Immunol 1992; 29: 739-49
85. 85. Cardot E, Pestel J, Callebaut I, et al. Specific activation of platelets from patients allergic to Dermatophagoides pteronyssinus by synthetic peptides derived from the allergen Der p I. Int Arch Allergy Immunol 1992; 98: 127-34
86. 86. Ferguson TA, Peters Jr T, Reed R, et al. Immunoregulatory properties of antigenic fragments from bovine serum albumin. Cell Immunol 1983; 78: 1-12
87. 87. Norman PS, Ishizaka K, Lichtenstein LM, et al. Treatment of ragweed hay fever with urea-denatured antigen E. J Allergy Clin Immunol 1980; 66: 336-41
88. 88. Litwin A, Pesce AJ, Michal JG. Regulation of the human immune response to allergens by immunosuppressive allergenic fragmnets. 1. Peptic fragments of honey bee venom phospholipase A2. Int Arch Allergy Appl Immunol 1988; 87 94): 361-6
89. 89. Morgenstern JP, Griffith IJ, Brauer AW, et al. Amino acid sequence of Fel d.I, the major allergen of the domestic cat: protein sequence analysis and cDNA cloning. Proc Natl Acad Sci USA 1991; 88: 9690-4
90. 90. Rogers BL, Morgenstern JP, Garman RD, et al. Recombinant Fel d.I: Expression, purification, IgE binding and reaction with cat-allergic human T cells. Mol Immunol 1993; 30: 559-68
91. 91. Nicodemus C, Philip G, Jones N, et al. Integrated clinical experience with tolerogenic peptides. Int Arch Allergy Immunol 1997; 113: 326-8
92. 92. Norman PS, Nicodemus CF, Creticos PS, et al. Clinical and immunologic effects of component peptides in Allervax Cat. Int Arch Allergy Immunol 1997; 113: 224-6
93. 93. Pène J, des-Roches A, Paradis L. Immunotherapy with Fel d I peptide decreases IL-4 release by peripheral blood T cells of cat-allergic patients. J Allergy Clin Immunol 1998; 102: 571-8
94. 94. Ball T, Vrtala S, Sperr WR, et al. Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. J Biol Chem 1994; 269: 28323-8
95. 95. Raz E, Tighe H, Sato Y, et al. Preferential induction of a Th 1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996; 93: 5141-5
96. 96. Montgomery DL, Ulmer JB, Donnelly JJ, et al. DNA vaccines. Pharmacol Ther 1997; 74: 195-205
97. 97. Hsu CH, Chua KY, Tao MH, et al. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization [see comments]. Nat Med 1996; 2: 540-4
98. 98. Spiegelberg HL, Orozco EM, Roman M, et al. DNA immunization: a novel approach to allergen-specific immunotherapy. Allergy 1997; 52: 964-70
99. 99. Goodman J, Van Unden J, Kobayashi H, et al. DNA immunotherapeutics: new potential treatment modalities for allergic diseases. Int Arch Allergy Immunol 1998; 116: 177-87
100. 100. Aalberse RC, Dieges PH, Knul-Bretlova V, et al. IgG4 as a blocking antibody. Clin Rev Allergy 1983; 1: 289-302
101. 101. Bousquet J, Maasch H, Martinot B, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol 1988; 82: 439-46
102. 102. Birkner T, Rumpold H, Jarolim E, et al. Evaluation of immunotherapy-induced changes in specific IgE, IgG and IgG subclasses in birch pollen allergic patients by means of immunoblotting. Correlation with clinical response. Allergy 1990; 45: 418-26
103. 103. Menz G, Dolecek C, Schonheit-Kenn U, et al. Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet v 1, the major birch pollen allergen. Clin Exp Allergy 1996; 26: 50-60
104. 104. Pauli G, Oster JP, Deviller P, et al. Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: diagnostic value for birch pollen and associated allergies. J Allergy Clin Immunol 1996; 97: 1100-9
105. 105. Vrtala S, Susani M, Sperr WR, et al. Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p2, Phl p 5). J Allergy Clin Immunol 1996; 97: 781-7
106. 106. Tame A, Sakiyama Y, Kobayashi I, et al. Differences in titres of IgE, IgG4 and other IgG subclass anti-Der p 2 antibodies in allergic and non-allergic patients measured with recombinant allergen. Clin Exp Allergy 1996; 26: 43-9
107. 107. Kobayashi I, Sakiyama Y, Tame A, et al. IgE and IgG4 antibodies from patients with mite allergy recognize different epitopes of Dermatophagoides pteronyssinus group II antigen (Der p2). J Allergy Clin Immunol 1996; 97: 638-45
108. 108. Visco V, Dolecek C, Denepoux S, et al. Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v1. J Immunol 1996; 157: 956-62
109. 109. Lebecque S, Dolecek C, Laffler S, et al. Immunologic characterization of monoclonal antibodies which modulate human immunoglobulin E binding to the major birch pollen allergen Bet v 1. J Allergy Clin Immunol 1997; 99: 374-84
110. 110. Hebert J. Bernier D, Boulin Y, et al. Generation of anti-idiotypic and anti-anti-idiotypic monoclonal antibodies in the same fusion. Support of Jerne's Network Theory. J Immunol 1990; 144: 4256-61
111. 111. Boutin Y, Jobin M, Bernier D, et al. Biological activity of monoclonal anti-idiotypic antibody representing the internal image of the major allergenic component of Lolium perenne pollen. Int Arch Allergy Immunol 1993; 102: 10-4
112. 112. Machiels JJ, Somville MA, Lebrun PM, et al. Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen-antibody complexes. J Clin Invest 1990; 85: 1024-35
113. 113. Machiels JJ, Buche M, Somville MA, et al. Complexes of grass pollen allergens and specific antibodies reduce allergic symptoms and inhibit the seasonal increase of IgE antibody. Clin Exp Allergy 1990; 20: 653-60
114. 114. Boulin Y, Jobin M, Bedard PM, et al. Possible dual role of anti-idiotypic antibodies in combined passive and active immunotherapy in honeybee sting allergy. J Allergy Clin Immunol 1994; 93: 1039-46
115. 115. Presta L, Shields R, O'Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994; 269: 26368-73
116. 116. Demoly P. Bousquet J. Anti-IgE therapy for asthma. Am J Respir Crit Care Med 1997; 155: 1825-7
117. 117. Corne J, Djukanovic R, Thomas L, et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest 1997; 99: 879-87
118. 118. Boulet LP, Chapman KR, Cote J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response (see comments). Am J Respir Crit Care Med 1997; 155: 1835-40
119. 119. Fahy JV, Fleming HE. Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early-and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155: 1828-34
120. 120. Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunul 1997; 100: 110-21
121. 121. Hellman L. Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine. Eur J Immunol 1994; 24: 415-20
122. 122. Stadler B, Rudolf M, Vogel M, et al. Can active immunization redirect an anti-TgE immune response? Int Arch Allergy Immunol 1997. In press
123. 123. Okudaira H, Mori A, Mikami T, et al. Selective suppression of IL-5 synthesis by OM-01 - pinpoint treatment of atopic diseases by IL-5 gene transcription inhibitor, Int Arch Allergy Immunol 1997; 113: 331-4
124. 124. Aversa G, Carballido J, Punnonen J, et al. SLAM and its role in T cell activation and Th cell responses. Immunol Cell Biol 1997; 75: 202-5
125. 125. Danzig M, Cuss F. Inhibition of interleukin-5 with a monoclonal antibody attenuates allergic inflammation. Allergy 1997; 52: 787-94
126. 126. Takeda K, Kishimoto T, Akira S. STAT6: its role in interleukin 4-mediated biological functions. J Mol Med 1997; 75: 317-26
127. 127. Paul WE. Interleukin 4: signalling mechanisms and control of T cell differentiation. Ciba Found Symp 1997; 204; 208-16
128. 128. Akimoto T, Numata F, Tamura M, et al. Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT) 6-deficient mice. J Exp Med 1998; 187: 1537-42
129. 129. Li JT, Yunginger JW, Reed CE, et al. Lack of suppression of IgE production by recombinant interferon gamma: a controlled trial in patients with allergic rhinitis. J Allergy Clin Immunol 1990; 85: 934-40
130. 130. Trinchieri G. Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol 1998; 16: 365-96
131. 131. Marinaro M, Boyaka PN, Finkelman FD, et al. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J Exp Med 1997; 185: 415-27
132. 132. Nyce JW, Metzger WJ. DNA antisense therapy for asthma in an animal model. Nature 1997; 385: 721-5
133. 133. Richardson PJ. Asthma. Blocking adenosine with antisense. Nature 1997; 385: 684-5
134. 134. Bjorck P, Larsson S, Andang M, et al. IL-6 antisense oligonucleotides inhibit IgE production in IL-4 and anti-CD40-stimulated human B-lymphocytes. Immunol Lett 1998; 61: 1-5
135. 135. Fekete B, Sagi J, Szemzo A, et al. Inhibition of IgE production by epsilon (epsilon) chain-specific antiscnsc oligonucleotides (AOs) studied on human myeloma cell line U266 and peripheral blood mononuclear cells of a patient with hypereosinophilia. Immunol Lett 1997; 58: 181-90
136. 136. McDonnell JM, Beavil AJ, Mackay GA, et al. Structure-based design of peptides that inhibit IgE binding to its high-affinity receptor Fc epsilon RI. Biochem Soc Trans 1997; 25: 387-92
137. 137. Stanworth DR, Jones VM, Lewin IV, et al. Allergy treatment with a peptide vaccine [see comments]. Lancet 1990; 336: 1279-81